Risk factors
Aardvark Therapeutics (AARD) risk factors
Item 1A of every Aardvark Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors100 risks
Aardvark Therapeutics has accumulated an $115.9 million deficit, driven by rising R&D and G&A expenses. The company relies on its $110.0 million in cash, cash equivalents, and short-term investments, which management expects will fund operations into the second quarter of 2027. Future survival depends entirely on successful clinical trials, regulatory approvals, and raising additional capital through equity or debt financings.
Filed Mar 23, 2026